Shaji Kumar is Professor of Medicine at the Mayo Clinic, Rochester, MN and a Consultant Hematologist within the Division of Hematology. He has an active research group working on a wide range of subjects, ranging from smoldering myeloma and the risk of disease progression to molecular questions surrounding the bone marrow microenvironment and its influence on tumor growth. He has a strong focus on the development of novel drugs, and is the lead researcher on numerous phase I and phase II trials, looking at synergistic drug regimens. He also has published widely in the field of amyloidosis.
Dr. Kumar completed his medical degree and clinical residency in Internal Medicine, at the All India Institute of Medical Sciences in New Delhi. In 1997 he moved to the Mayo Clinic Graduate School of Sciences to take up a clinical residency in Internal Medicine, before becoming a fellow in Hematology and Oncology, and subsequently rising to the position of Professor of Medicine.
Dr. Kumar is on the editorial board for a number of prominent medical journals. He is also Treasurer of the International Myeloma Society (IMS) and on the clinical advisory board for Managing Myeloma. He is the co-chair of the NCI Multiple Myeloma (MM) steering committee and also chair of the NCCN myeloma panel. He is the Vice Chair of the steering committee for the Multiple Myeloma Research Consortium (MMRC), and in April 2017 he joined the Steering Committee for the Multiple Myeloma Hub.